Synthroid vs Armour Thyroid: Cost and Access Head-to-Head

What Each Drug Actually Is

Synthroid is the brand name for levothyroxine sodium, a synthetic form of the T4 thyroid hormone. The American Thyroid Association (ATA) 2014 guidelines recommend levothyroxine as the standard replacement therapy for hypothyroidism based on decades of clinical use, predictable pharmacokinetics, and consistent potency across lots [1].

Levothyroxine: The Synthetic Standard

Levothyroxine delivers a single hormone (T4), which the body converts to the active T3 form through peripheral deiodinase enzymes. The FDA has approved multiple generic manufacturers, and the drug appears on the WHO Model List of Essential Medicines. This multi-source supply chain keeps prices low and inventory stable. The FDA's Approved Drug Products database lists over a dozen AB-rated generic levothyroxine products as of 2025 [2].

Armour Thyroid: The Desiccated Alternative

Armour Thyroid is a natural desiccated thyroid (NDT) extract derived from porcine thyroid glands. It provides both T4 and T3 in a fixed ratio of roughly 4.22:1. The product predates the 1938 Federal Food, Drug, and Cosmetic Act and has never gone through the modern FDA new drug approval process, though the FDA considers it an approved drug under legacy marketing provisions [3]. AbbVie (formerly Allergan, formerly Forest Laboratories) is the sole manufacturer.

Monthly Cost Breakdown

The price gap between these two medications is significant. For a patient taking a standard replacement dose, the numbers look very different depending on insurance status and pharmacy choice.

Cash Prices Without Insurance

Generic levothyroxine at a 90-day supply from large chain pharmacies (CVS, Walgreens, Walmart) typically runs $10 to $25 for common strengths like 50 mcg, 75 mcg, or 100 mcg. Brand-name Synthroid without insurance costs $130 to $170 for a 30-day supply, though the manufacturer offers a copay savings card that can reduce this [4]. Armour Thyroid 60 mg (1 grain), the most commonly prescribed strength, averages $50 to $90 for a 30-day cash-pay supply. That price has risen roughly 300% since 2009, when the same supply cost under $15.

With Insurance Coverage

Most commercial and government formularies place generic levothyroxine on Tier 1, meaning copays of $0 to $10 per fill. The CDC's National Health and Nutrition Examination Survey data show levothyroxine ranks among the top five most prescribed medications in the United States, with over 100 million prescriptions dispensed annually [5]. That volume ensures every major insurer covers it. Armour Thyroid sits on Tier 2 or Tier 3 at plans that cover it, and some plans exclude it entirely. Patients on Medicare Part D may find Armour Thyroid in a non-preferred brand tier, with copays of $40 to $60 per fill.

Insurance and Formulary Access

Coverage differences between these two drugs reflect a pattern common across brand-vs-generic dynamics, but the gap here is wider than usual because NDT lacks the clinical-guideline endorsement that drives formulary inclusion.

Commercial Insurance

Blue Cross Blue Shield, UnitedHealthcare, Aetna, and Cigna all place generic levothyroxine on their lowest cost-sharing tier. Brand Synthroid may require step therapy (try generic first) before the plan covers it. Armour Thyroid coverage varies sharply by plan. Some UnitedHealthcare plans list it as a non-preferred brand. Several Anthem plans require prior authorization, and some Cigna regional plans exclude it from the formulary outright [6].

Medicare and Medicaid

Medicare Part D plans must cover at least one drug in each therapeutic class. Levothyroxine satisfies that requirement for thyroid hormone replacement, so plans have no obligation to also cover Armour Thyroid. A 2020 analysis of CMS formulary data showed that only 62% of standalone Part D plans included any NDT product. Medicaid coverage depends on state-level decisions. States with restrictive preferred drug lists (Texas, California, Florida) often limit NDT coverage to cases where a patient has documented intolerance or allergy to levothyroxine, per state Medicaid pharmacy guidelines [7].

VA and TRICARE

The VA National Formulary includes levothyroxine. Armour Thyroid can be prescribed through the VA but typically requires a non-formulary request and clinical justification. TRICARE covers levothyroxine at a $0 copay for generic through the mail-order pharmacy (Express Scripts). Armour Thyroid falls into a higher cost-sharing tier [8].

Supply Chain and Availability

Drug availability matters as much as price. A medication that costs less but cannot be filled on time creates real clinical problems. Levothyroxine has over a dozen approved generic manufacturers in the U.S., including Mylan, Sandoz, Lannett, and others listed in the FDA Orange Book [9]. If one manufacturer experiences a shortage, pharmacies can substitute from another.

Armour Thyroid Supply Disruptions

Armour Thyroid has a single manufacturer. That concentration has led to repeated shortages. In 2009, a raw-material supply issue created a multi-month gap. In 2012, reformulation complaints drove some patients to other NDT brands (Nature-Throid, WP Thyroid), both of which later experienced their own FDA-reported shortages. Nature-Throid and WP Thyroid were unavailable for extended periods between 2020 and 2023 [10]. The American Society of Health-System Pharmacists drug shortage database has flagged NDT products multiple times in the past decade [11].

Pharmacy Stocking Patterns

Large chains reliably stock levothyroxine in all common strengths. Armour Thyroid stocking is less consistent at independent pharmacies. Patients in rural areas may need to use mail-order pharmacies or compounding pharmacies for NDT access. Compounded desiccated thyroid is an option, but it lacks the batch-to-batch consistency testing required of manufactured products and may not be covered by insurance.

Clinical Evidence: Does the Cheaper Drug Work as Well?

Cost comparisons are meaningless if one drug performs significantly better. The clinical data show that, for most patients, outcomes are similar.

The ATA Guidelines Position

The 2014 ATA guidelines for the treatment of hypothyroidism recommend levothyroxine monotherapy as the standard of care, citing its long track record, consistent potency, once-daily dosing, and well-understood pharmacokinetics [1]. The guideline panel noted insufficient evidence to recommend NDT, T3/T4 combination therapy, or T3 monotherapy over levothyroxine alone. These guidelines carry weight because they inform formulary decisions at major insurers and pharmacy benefit managers. A 2012 Endocrine Society clinical practice guideline reached a similar conclusion, recommending levothyroxine monotherapy while acknowledging that a subset of patients report subjective improvement on combination products [12].

The Hoang 2013 Crossover Trial

The most-cited head-to-head study is Hoang et al. (2013), a double-blind, randomized crossover trial comparing desiccated thyroid extract to levothyroxine in 70 patients over two 16-week treatment periods. TSH levels were equivalent between groups. Free T4 was lower and free T3 was higher during the NDT phase, which is expected given the exogenous T3 content. No significant difference appeared in symptoms, neurocognitive function, or quality-of-life scores. Forty-nine percent of patients preferred desiccated thyroid at the end of the study, 19% preferred levothyroxine, and 32% had no preference. Patients lost an average of 1.5 kg more on NDT. That preference signal was statistically significant [13].

What the Preference Signal Means for Cost Decisions

A 49% preference rate does not prove clinical superiority. The study was powered for TSH equivalence, not symptom superiority, and the weight-loss difference was modest. But for a patient paying $60 more per month for Armour Thyroid who belongs to that 49%, the preference may justify the cost. For the other 51%, levothyroxine at a fraction of the price achieves the same biochemical control. A 2018 systematic review in Thyroid analyzed nine trials comparing NDT or T3/T4 combination therapy to levothyroxine monotherapy and concluded that current evidence does not support routine use of combination therapy, though individual patients may benefit [14].

Who Should Consider Armour Thyroid Despite the Higher Cost

Not every patient will do well on levothyroxine alone. The 2014 ATA guidelines acknowledge that a trial of combination T3/T4 therapy is reasonable for patients with persistent symptoms despite optimal TSH levels on levothyroxine monotherapy [1].

Clinical Scenarios Favoring NDT

Patients with documented poor conversion of T4 to T3 (low free T3 despite adequate free T4 and TSH) may benefit from the T3 content in Armour Thyroid. Polymorphisms in the DIO2 gene (deiodinase type 2) have been associated with impaired T4-to-T3 conversion and with patient preference for combination therapy in some studies [15]. A 2009 study in the Journal of Clinical Endocrinology & Metabolism found that patients carrying the Thr92Ala DIO2 polymorphism reported worse well-being on levothyroxine monotherapy compared to wild-type patients [15].

When Levothyroxine is the Clear Winner on Value

For newly diagnosed hypothyroidism, patients without residual symptoms on levothyroxine, and patients on tight budgets or restrictive formularies, generic levothyroxine is the better financial choice. A 90-day mail-order supply at $10 versus $180+ for Armour Thyroid represents over $680 in annual savings. That gap compounds for patients on fixed incomes, particularly Medicare beneficiaries in the coverage gap [16].

How to Switch Between the Two

Switching from Synthroid to Armour Thyroid (or vice versa) requires dose recalculation because the drugs are not milligram-equivalent.

Conversion Ratios

The standard clinical conversion is approximately 100 mcg levothyroxine = 60 mg (1 grain) Armour Thyroid. This ratio is approximate. Armour Thyroid delivers roughly 38 mcg T4 and 9 mcg T3 per grain. Because T3 is roughly three to four times as potent as T4 at the receptor level, the effective thyroid hormone exposure may differ between drugs even at "equivalent" doses. The ATA guidelines recommend checking TSH 6 to 8 weeks after any switch and adjusting accordingly [1].

Insurance Hurdles When Switching

Switching from levothyroxine to Armour Thyroid may trigger a prior authorization if the plan requires step therapy documentation. Patients should ask their prescriber to include chart notes documenting persistent symptoms on levothyroxine, lab values, and the clinical rationale for the switch. Moving from Armour Thyroid to levothyroxine rarely faces formulary barriers.

Practical Tips to Reduce Costs for Either Drug

Regardless of which medication a patient uses, strategies exist to lower out-of-pocket spending.

For Levothyroxine Users

Request a 90-day supply through mail-order pharmacy. Many plans offer 90-day generic fills for the price of one 30-day copay. Walmart, Costco, and Mark Cuban's Cost Plus Drugs pharmacy sell generic levothyroxine for under $10 per 90 days at common doses. Do not switch between generic manufacturers without physician awareness, since bioequivalence ranges of 80 to 125% of the reference product can result in clinically meaningful TSH fluctuations for some patients [17].

For Armour Thyroid Users

Check manufacturer copay programs from AbbVie. Use GoodRx or RxSaver discount cards; these can reduce cash-pay prices by 20 to 40%. Ask your prescriber about 90-day fills. If supply disruptions hit, compounded desiccated thyroid from an accredited 503B outsourcing facility is a regulated alternative, though cost varies by pharmacy [18].

The Bottom Line on Cost vs. Effectiveness

Levothyroxine and Armour Thyroid produce equivalent TSH normalization in head-to-head data. Levothyroxine costs 60 to 80% less, appears on every major formulary, and has a redundant supply chain with over a dozen manufacturers. Armour Thyroid costs more, faces formulary restrictions, and depends on a single supplier. The 49% preference signal from Hoang et al. is real but does not override the access and affordability advantages of levothyroxine for patients without a specific clinical reason to use NDT [13]. For patients stable on levothyroxine with normal TSH and no residual symptoms, switching to Armour Thyroid for non-clinical reasons will increase spending by $500 to $1,000 per year without guaranteed symptomatic benefit.